Molecular PSMA Imaging and Targeted Radionuclide Therapy of Metastatic Prostate Cancer

There are currently several different FDA approved radiopharmaceuticals being used in both large academic and small practice settings to accurately stage and identify local and metastatic prostate cancer, including the recent FDA approval of 68GaPSMA-11 and 18F-DCFPyL for primary and metastatic prostate cancer. Given the widespread application of diagnostic radiopharmaceuticals, and the recent approval of 177Lu PSMA-617 (Pluvicto), there is great promise that the diagnosis and treatment of metastatic prostate cancer will be dramatically improved. This talk covers the scientific rational for PSMA PET and targeted radionuclide therapy and what to expect on the day of therapy.

Learning Objectives: 

1. Discuss next generation PSMA PET imaging agents into clinical practice.

2. Appraise the role that PSMA PET will play in the modern clinical practice and incorporate appropriate imaging protocols, reading criteria, and navigate common pitfalls.

3. Devise a practice with PSMA radiotheranostics including appropriate patient selection, treatment protocols, and methods to evaluate successful therapy.